Drug Trial Radar · NCT03984097
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 29, 2019
Primary completion
Mar 25, 2026
Study completion Mar 25, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen. The purpose of the safety/access cohort is to provide continued access to TAK-079 to participants previously enrolled to a TAK-079 parent study and to evaluate the long-term safety profile of TAK-079.
Conditions
- Multiple Myeloma
Interventions
TAK-079Drug
TAK-079 subcutaneously.
LenalidomideDrug
Lenalidomide orally.
DexamethasoneDrug
Dexamethasone orally.
BortezomibDrug
Bortezomib subcutaneously.
PomalidomideDrug
Pomalidomide orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Phase: RP2D of TAK-079Time frame: Up to Cycle 1 (Cycle length is equal to [=] 28 days)
- Safety Extension Phase: Number of Participants Reporting one or More Serious Adverse Events (SAEs)Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
- Safety Extension Phase: Number of Participants With Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
- Safety Extension Phase: Number of Participants Who Require Dose ModificationTime frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
- Safety Extension Phase: Number of Participants With TEAEs Leading to Treatment DiscontinuationTime frame: From first dose up to 30 days after the last dose of study drug (up to 4 years)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Pacific Cancer Care
Monterey, California
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Columbia University Medical Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Good Samaritan Hospital
Cincinnati, Ohio
Oregon Health & Science University
Portland, Oregon
MD Anderson Cancer Center
Houston, Texas
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.